Some view the COVID-19 pandemic as a reputational turning point for pharma and an opportunity to solidify a more positive impact on society. Many pharmaceutical companies are furthering this goal by incorporating ESG into their operations.
Acella Pharmaceuticals, LLC is voluntarily recalling one lot of 15-mg and one lot of 120-mg NP Thyroid®, Thyroid Tablets, USP [levothyroxine (T4) and liothyronine (T3)] to the consumer level.